FDA Workshop To Discuss Brain Tumor Trial Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
The Jan. 20 public meeting is next in a series of meetings on oncology endpoints.
You may also be interested in...
Talabostat SPA "Unnecessary" Given Available Cancer Guidance – Point Therapeutics
Special protocol assessment process for the dipeptidyl peptidase inhibitor would have delayed start of Phase III non-small cell lung cancer trials, exec says.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.